Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty

• ClinicalTrials.gov Identifier: NCT03845881
• Recruitment Status: Recruiting
• First Posted: February 19, 2019
• Last Update Posted: May 10, 2019
• Sponsor: Mayo Clinic
• Collaborators: Ambit Biosciences Corporation; Kern Medical Center
• Information provided by (Responsible Party): Benjamin K. Wilke, Mayo Clinic

Study Description

Brief Summary:

To help curb the use of opioid medications following orthopedic surgery investigators have developed a new multi-modal pain pathway. Investigators aim to compare this regimen with and without the inclusion of opioid medications. This study will be performed in a randomized, double-blinded, placebo-controlled fashion in patients undergoing primary total knee or total hip arthroplasty. Investigators hypothesize that the opioid devoid pathway will show equivalent pain scores to the pathway that includes opioids while also having less constipation, nausea, and vomiting following surgery. If successful, this would create a dramatic decrease in opioid consumption following orthopedic surgery while still providing appropriate pain relief to patients.

Condition or disease	Intervention/treatment	Phase
Total Knee Arthroplasty	Drug: Oxycodone; Drug: Placebo Oral Tablet	Early Phase 1

Detailed Description:

• Aim 1 will be to compare the postoperative pain levels both in the hospital setting as well as daily for two weeks following discharge between patients in the opioid treatment group and those in the non-opioid treatment group. This will be performed with clinical exams while in the hospital and with phone surveys on discharge. Results will be recorded using the Visual Analog Scale for pain scores.
• Aim 2 will be to compare the overall morphine equivalents used during hospitalization between the opioid and non-opioid treatment groups. This will be calculated based on the amount of intravenous breakthrough narcotic pain medication used in the hospital setting (divided by the total number of post-surgery hospitalization hours to account for varying lengths of stay). Investigators will also measure the total number of opioid pills (these would be placebo pills for the non-opioid group) consumed during the first two weeks post-discharge, and the post-surgery day on which opioid pills were discontinued, and compare these outcomes between the opioid and non-opioid groups.
• Aim 3 will be to compare postoperative constipation, nausea, and vomiting between the two treatment groups. This will be assessed with daily clinical examinations while in the hospital and with daily phone surveys on discharge. Constipation will be recorded as presence or absence, while nausea and vomiting will be measured using the Postoperative Nausea and Vomiting Scale.
• Aim 4 will be to compare the length of post-surgery hospitalization between the two treatment groups.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 50 participants
• Allocation: Randomized
• Intervention Model: Single Group Assignment
• Intervention Model Description: Multi-Modal Pain Protocol with and without Opioids Following Total Joint Arthroplasty
• Masking: Double (Participant, Investigator)
• Masking Description: The oxycodone and placebo tablets will be encapsulated by the research pharmacy prior to dispensing for blinding purposes.
• Primary Purpose: Treatment
• Official Title: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty
• Actual Study Start Date: April 10, 2019
• Estimated Primary Completion Date: February 28, 2020
• Estimated Study Completion Date: September 30, 2020

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Opioid; Multi-Modal Pain Protocol with Opioids Following Total Joint Arthroplasty	Drug: Oxycodone; The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
Placebo Comparator: Non Opioid; Multi-Modal Pain Protocol without Opioids Following Total Joint Arthroplasty	Drug: Placebo Oral Tablet; The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.

Outcome Measures

Primary Outcome Measures :

1. Pain Levels [ Time Frame: 2 weeks ]
   compare the postoperative pain levels both in the hospital setting as well as daily for two weeks following discharge between patients in the opioid treatment group and those in the non-opioid treatment group. This will be performed with clinical exams while in the hospital and with phone surveys on discharge. Results will be recorded using the Visual Analog Scale for pain scores. This scale ranges from 0 to 10, with zero being no pain and 10 being as bad as can be, and includes visual facial cues. Following this scale, investigators will also ask about sleep, activity, mood, and stress.

Secondary Outcome Measures :

1. Opioid Levels [ Time Frame: 2 weeks ]
   compare the overall morphine equivalents used during hospitalization between the opioid and non-opioid treatment groups. This will be calculated based on the amount of intravenous breakthrough narcotic pain medication used in the hospital setting (divided by the total number of post-surgery hospitalization hours to account for varying lengths of stay). Investigators will also measure the total number of opioid pills (these would be placebo pills for the non-opioid group) consumed during the first two weeks post-discharge, and the post-surgery day on which opioid pills were discontinued, and compare these outcomes between the opioid and non-opioid groups.
2. Side effects [ Time Frame: 2 weeks ]
   compare postoperative constipation, nausea, and vomiting between the two treatment groups. This will be assessed with daily clinical examinations while in the hospital and with daily phone surveys on discharge. Constipation will be recorded as presence or absence, while nausea and vomiting will be measured using the Postoperative Nausea and Vomiting Scale. This scaled is based off 2 questions related to nausea and vomiting which will be added together for a total score. Responses range from 0 to 3 and a total score of greater than or equal to 5 will be defined as clinically important.
3. Length of hospitalization [ Time Frame: 2 weeks ]
   compare the length of post-surgery hospitalization between the two treatment groups.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 89 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Age > 18 and < 90 years.
2. Willing to participate in the study and competent to provide informed consent.
3. Willing to comply with protocol procedures.
4. Has an underlying diagnosis of osteoarthritis indicated for knee arthroplasty.

Exclusion Criteria:

1. A diagnosis of renal or liver disease
2. If a patient has a contraindication to receiving a spinal anesthetic or pain catheter
3. The patient must not have taken any narcotic medications during the 3 months leading up to the surgery
4. The patient must not be allergic or intolerant to a medication used in the multi-modal pain pathway
5. Revision hip or knee arthroplasty
6. If a patient is being treated under worker's compensation
7. If a patient has diabetes
8. Unable to take Aspirin 325 mg twice daily for deep venous thromboprophylaxis

Contacts and Locations

Contacts

Contact: Lori Chase, CCRP; (904) 953-3464; Chase.Lori@mayo.edu

Locations

United States, Florida

Mayo Clinic in Florida; Recruiting

Jacksonville, Florida, United States, 32224

Contact: Lori Chase, CCRP 904-953-3464 Chase.Lori@mayo.edu

Sponsors and Collaborators

Mayo Clinic

Ambit Biosciences Corporation

Kern Medical Center

Investigators

• Principal Investigator: Benjamin Wilke, MD; Mayo Clinic

More Information

Additional Information:

Mayo Clinic Clinical Trials 

• Responsible Party: Benjamin K. Wilke, Principal Investigator, Mayo Clinic
• ClinicalTrials.gov Identifier: NCT03845881
• Other Study ID Numbers: 18-004256
• First Posted: February 19, 2019
• Last Update Posted: May 10, 2019
• Last Verified: May 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Analgesics, Opioid; Oxycodone; Narcotics; Central Nervous System Depressants; Physiological Effects of Drugs; Analgesics; Sensory System Agents; Peripheral Nervous System Agents